Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Where does neoadjuvant chemotherapy in advanced ovarian cancer fit in clinical practice?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.01.19
Views: 426

Prof Sean Kehoe - University of Birmingham, Birmingham, UK

Prof Sean Kehoe speaks to ecancer at BGICC 2019 in Cairo about the use of neoadjuvant chemotherapy in advanced ovarian cancer.

He explains that it has been found that women with stage 4 disease have an improved overall survival if they were given neoadjuvant chemotherapy.

Prof Kehoe states that neoadjuvant chemotherapy can also be preferable for patients with a poor performance status.

In these instances if the patient's quality of life improves it can be safer to operate on them.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation